Director/PDMR Shareholding

RNS Number : 2271C

GlaxoSmithKline PLC

27 September 2018

 

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms E Walmsley
b)	Position/status	Chief Executive Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Following the vesting on 23 September 2018 of 25% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Ms Walmsley will receive a cash payment of £154,279.74 less applicable tax withholding in respect of 10,075.600 notional Ordinary Shares.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.314 10,075.600
d)	Aggregated information Aggregated volume Price	n/a (single transaction)
e)	Date of the transaction	2018-09-23
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr R G Connor
b)	Position/status	President, Global Vaccines
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Following the vesting on 23 September 2018 of 25% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Mr Connor will receive a cash payment of £123,438.19 less applicable tax withholding in respect of 8,060.480 notional Ordinary Shares.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.314 8,060.480
d)	Aggregated information Aggregated volume Price	n/a (single transaction)
e)	Date of the transaction	2018-09-23
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Mr D S Redfern
b)	Position/status	Chief Strategy Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Following the vesting on 23 September 2018 of 25% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Mr Redfern will receive a cash payment of £123,438.19 less applicable tax withholding in respect of 8,060.480 notional Ordinary Shares.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.314 8,060.480
d)	Aggregated information Aggregated volume Price	n/a (single transaction)
e)	Date of the transaction	2018-09-23
f)	Place of the transaction	n/a

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Ms C Thomas
b)	Position/status	SVP, Human Resources
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial  instrument	Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Following the vesting on 23 September 2018 of 25% of an award made on 12 June 2014 under the GlaxoSmithKline Deferred Investment Award Plan, Ms Thomas will receive a cash payment of £123,438.19 less applicable tax withholding in respect of 8,060.480 notional Ordinary Shares.
c)	Price(s) and volume(s)	Price(s) Volume(s) £15.314 8,060.480
d)	Aggregated information Aggregated volume Price	n/a (single transaction)
e)	Date of the transaction	2018-09-23
f)	Place of the transaction	n/a

 

END

 

 

DSHEDLFLVKFLBBD